이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Aptose Biosciences 관리

관리 기준 확인 3/4

Aptose Biosciences' CEO는 William Rice, Oct2013 에 임명되었습니다 의 임기는 10.67 년입니다. 총 연간 보상은 $ 924.67K, 67.4% 로 구성됩니다. 67.4% 급여 및 32.6% 보너스(회사 주식 및 옵션 포함). 는 CA$ 41.74K 가치에 해당하는 회사 주식의 0.16% 직접 소유합니다. 41.74K. 경영진과 이사회의 평균 재임 기간은 각각 2 년과 10.7 년입니다.

주요 정보

William Rice

최고 경영자

US$924.7k

총 보상

CEO 급여 비율	67.4%
CEO 임기	10.8yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	2.1yrs
이사회 평균 재임 기간	10.8yrs

최근 관리 업데이트

Recent updates

Companies Like Aptose Biosciences (TSE:APS) Are In A Position To Invest In Growth

Sep 30

Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling

Feb 07

Is Aptose Biosciences Inc.'s (TSE:APS) Shareholder Ownership Skewed Towards Insiders?

Jan 03

We're Not Very Worried About Aptose Biosciences' (TSE:APS) Cash Burn Rate

Nov 29

Jotin Marango Is The Senior VP & Chief Business Officer of Aptose Biosciences Inc. (TSE:APS) And They Just Sold 26% Of Their Shares

Jul 11

Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling

Jun 27

CEO 보상 분석

William Rice 의 보수는 Aptose Biosciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$47m
Dec 31 2023	US$925k	US$623k	-US$51m
Sep 30 2023	n/a	n/a	-US$49m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	-US$44m
Dec 31 2022	US$2m	US$599k	-US$42m
Sep 30 2022	n/a	n/a	-US$56m
Jun 30 2022	n/a	n/a	-US$58m
Mar 31 2022	n/a	n/a	-US$61m
Dec 31 2021	US$2m	US$582k	-US$65m
Sep 30 2021	n/a	n/a	-US$56m
Jun 30 2021	n/a	n/a	-US$58m
Mar 31 2021	n/a	n/a	-US$60m
Dec 31 2020	US$12m	US$582k	-US$55m
Sep 30 2020	n/a	n/a	-US$48m
Jun 30 2020	n/a	n/a	-US$42m
Mar 31 2020	n/a	n/a	-US$32m
Dec 31 2019	US$2m	US$562k	-US$26m
Sep 30 2019	n/a	n/a	-US$25m
Jun 30 2019	n/a	n/a	-US$24m
Mar 31 2019	n/a	n/a	-US$28m
Dec 31 2018	US$2m	US$540k	-US$29m
Sep 30 2018	n/a	n/a	-US$26m
Jun 30 2018	n/a	n/a	-US$23m
Mar 31 2018	n/a	n/a	-US$15m
Dec 31 2017	US$983k	US$520k	-US$12m

보상 대 시장: William 의 총 보상 ($USD 924.67K )은 Canadian 시장( $USD 175.07K ).

보상과 수익: William 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

William Rice (65 yo)

10.8yrs

테뉴어

US$924,668

보상

Dr. William G. Rice, Ph D., had served as an Independent Director of Oncolytics Biotech Inc. since June 08, 2015 until June 30, 2021. He has been the Chief Executive Officer and President of Aptose Bioscie...

리더십 팀

이름	위치	테뉴어	보상	소유권
William Rice	Chairman	10.8yrs	US$924.67k	0.16% $ 35.2k
Fletcher Payne	Senior VP	2.1yrs	US$611.37k	0.033% $ 7.6k
Rafael Bejar	Senior VP & Chief Medical Officer	4.5yrs	US$750.08k	0.033% $ 7.6k
Marc Wiles	Senior Vice President of Regulatory Affairs	less than a year	데이터 없음	데이터 없음
Brooks Ensign	VP & Controller	1.4yrs	데이터 없음	데이터 없음

2.1yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 관리: APS 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
William Rice	Chairman	10.8yrs	US$924.67k	0.16% $ 35.2k
Mark Vincent	Independent Director	16.8yrs	US$127.68k	0.0020% $ 445.7
Bernd Seizinger	Independent Director	1.8yrs	US$132.17k	0.077% $ 17.5k
Denis Burger	Lead Independent Director	16.8yrs	US$172.17k	0.0066% $ 1.5k
Stephen Howell	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Daniel Von Hoff	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Erich Platzer	Independent Director	9.6yrs	US$123.67k	0.15% $ 34.7k
Warren Whitehead	Independent Director	13.3yrs	US$122.68k	0.0046% $ 1.0k
Brian Druker	Chairman of Scientific Advisory Board	10.8yrs	데이터 없음	데이터 없음
Michael Andreeff	Member of Scientific Advisory Board	9.3yrs	데이터 없음	데이터 없음
Carol Ashe	Independent Director	5.9yrs	US$123.67k	0.0073% $ 1.6k

10.8yrs

평균 재임 기간

71.5yo

평균 연령

경험이 풍부한 이사회: APS 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.7 년).

Aptose Biosciences 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Aptose Biosciences Inc., Annual General Meeting, May 28, 2024

Aptose Biosciences Inc. Appoints Fletcher Payne as Chief Business Officer

Independent Director recently bought CA$72k worth of stock

Insufficient new directors

Aptose Biosciences Inc. Appoints Bernd R. Seizinger to the Board of Directors

Aptose Appoints Fletcher Payne as Chief Financial Officer

Recent updates

Aptose Biosciences Inc. has completed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $4.43325 million.

New major risk - Financial position

Aptose Biosciences Inc. to Report Q1, 2024 Results on May 14, 2024

Aptose Biosciences Receives a Letter from the Nasdaq Stock Market Stating the Company Was Not in Compliance with Nasdaq Listing Rule 5550(b)(1)

New major risk - Negative shareholders equity

Aptose Biosciences Inc., Annual General Meeting, May 28, 2024

Aptose Biosciences Inc. to Report Q4, 2023 Results on Mar 26, 2024

Aptose Biosciences Receives Deficiency Letter from The Nasdaq Stock Market LLC

Aptose Biosciences Inc. announced that it has received $4 million in funding from Hanmi Pharm. Co., Ltd.

New major risk - Shareholder dilution

Aptose Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $16.799998 million.

Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $16.799998 million.

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

Aptose Biosciences Inc. Appoints Fletcher Payne as Chief Business Officer

New major risk - Financial position

Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting

Aptose Biosciences Inc. Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

New major risk - Share price stability

Aptose Biosciences Inc. to Report Q3, 2023 Results on Nov 09, 2023

Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th

Independent Director recently bought CA$72k worth of stock

Aptose Biosciences Inc. Provides A Recent Update from an Ongoing Aptivate Phase 1/2 Clinical Trial with the Company's Lead Agent, Tuspetinib

Aptose Biosciences Inc. announced that it expects to receive CAD 7 million in funding from Hanmi Science Co., Ltd.

New minor risk - Share price stability

Aptose Biosciences Inc. to Report Q2, 2023 Results on Aug 10, 2023

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

Aptose Biosciences Inc. Presents Highlights from Clinical Update

Aptose Biosciences Inc. announced that it expects to receive CAD 25 million in funding

Forecast to breakeven in 2025

Here's Why We're Watching Aptose Biosciences' (TSE:APS) Cash Burn Situation

Aptose Biosciences Inc. Updates Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations

We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate

Aptose Biosciences Inc. Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib

Insufficient new directors

Aptose Biosciences Inc. to Report Q3, 2022 Results on Nov 01, 2022

Aptose Biosciences Inc. Appoints Bernd R. Seizinger to the Board of Directors

Aptose Biosciences Inc.’s New G3 Formulation of Luxeptinib Boosts Bioavailability

We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate

Aptose Biosciences Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department Regarding Minimum Bid Price Requirement

Aptose Biosciences Inc. to Report Q2, 2022 Results on Aug 02, 2022

Aptose Appoints Fletcher Payne as Chief Financial Officer

Aptose Receives Fast Track Designation for Hm43239 in Relapsed/Refractory Aml Patients and Flt3 Mutation

Insufficient new directors

Aptose Biosciences Inc. to Report Q1, 2022 Results on May 09, 2022

Aptose Biosciences Inc. Announces Resignation of Dr. Jotin Marango as Chief Financial Officer

We Think Aptose Biosciences (TSE:APS) Needs To Drive Business Growth Carefully

Aptose Biosciences Inc. Provides Update on APTO-253 Program

Independent Director recently bought CA$408k worth of stock

Aptose Biosciences Inc. Announces HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia

Companies Like Aptose Biosciences (TSE:APS) Are In A Position To Invest In Growth

Insufficient new directors

Independent Director recently sold CA$83k worth of stock

Aptose Presents Highlights from EHA2021 Virtual Congress During Corporate Update Event

Consensus forecasts updated

Executive VP, Corporate Secretary, CFO & COO has left the company

Consensus revenue estimates increase to US$928.6k

Aptose Biosciences Inc. to Report Q4, 2020 Results on Mar 23, 2021

New 90-day low: CA$5.06

Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling

Is Aptose Biosciences Inc.'s (TSE:APS) Shareholder Ownership Skewed Towards Insiders?

Independent Director exercised options and sold CA$53k worth of stock

New 90-day high: CA$9.13

We're Not Very Worried About Aptose Biosciences' (TSE:APS) Cash Burn Rate

Aptose Biosciences Inc. to Present CG-806 and APTO-253 Data At the 2020 Ash Annual Meeting

Aptose Biosciences Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: CA$6.30

Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid Leukemia